All

INTENTO DESIGN cooperates with STMICROELECTRONICS to accelerate analog design and migration of FD-SOI chips at functional level
12 June 2018

INTENTO DESIGN cooperates with STMICROELECTRONICS to accelerate analog design and migration of FD-SOI chips at functional level

Intento Design has announced its collaboration with STMicroelectronics (ST) in pushing forward its ID-XploreTM EDA software aimed to solve the critical design challenges in the...

Read the press release
The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK
12 April 2018

The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK

Humedics GmbH, a specialist in real-time measurement of individual liver function, today announced that the company has received Marketing Authorization for its diagnostic...

Read the press release
Seventure Partners announces that BPCE invests in its institutional funds, DIGITAL OPPORTUNITIES FUND
31 January 2018

Seventure Partners announces that BPCE invests in its institutional funds, DIGITAL OPPORTUNITIES FUND

Paris, 31st January 2018 – Seventure Partners, a leading European player in innovation financing and affiliate of Natixis Investment Managers, announces today the second...

Read the press release
MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
8 March 2018

MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation

MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...

Read the press release
Seventure Partners Life Sciences Investing Update – H2 2017
18 January 2018

Seventure Partners Life Sciences Investing Update – H2 2017

“2017 ended on a high note. Our Health For Life Capital™ investment vehicle has backed some truly remarkable disruptive technologies over the second half of the year and...

Read the press release
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
7 December 2017

Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...

Read the press release
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
1 December 2017

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy

New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys

Read more

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse